23 Drug Discovery, Pharmaceuticals & Cannabis Testing New assay kit transforms drug bioavailability testing


A new PhysioMimix® Bioavailability Assay Kit: Human 18 has been launched, offering researchers the ability to profile human oral drug bioavailability in vitro within their own laboratories. This innovative kit from CN Bio builds on advanced multi-organ Gut/Liver-on-a-chip technology, helping accelerate drug development by addressing limitations of traditional approaches and supporting safer, more effective clinical progression.


Accurately predicting bioavailability is a critical step in preclinical drug development, guiding safe dosage decisions in the clinic. Current methods, including in vitro assays, animal studies, and computational models, face challenges such as limited complexity in 2D cell cultures and poor translatability from animal data. The new assay kit provides a streamlined and predictive solution, enabling earlier and more accurate profiling of bioavailability to de-risk drug development pipelines.


Developed after the success of a similar assay offered through an ADME Contract Research Service earlier this year, the PhysioMimix Bioavailability Assay Kit: Human 18 has been optimised into a convenient format for independent use. It is designed for use with the PhysioMimix® Multi-organ System, integrating human-derived models of the gut and liver into a single system to simulate key processes of drug absorption, metabolism, and clearance. This dual-organ approach uniquely supports both oral and intravenous dosing, allowing researchers to evaluate candidates with precision.


The Gut/Liver-on-a-chip model combines Altis Biosystems’ RepliGut® Jejunum model with a highly characterised Liver-on-a-chip, developed in partnership with Altis Biosystems. The system fluidically links the two organs, accurately recapitulating processes such as intestinal metabolism and hepatic clearance. By enabling up to 18 replicates, the kit provides researchers with robust data to guide candidate selection, improve study design, and minimise the use of animal models.


Dr Yassen Abbas, Lead Scientist, highlighted that the kit reduces the burden of assay development, enabling labs to quickly adopt advanced organ-on-a-chip technology. Dr Ben Scruggs, CEO of Altis Biosystems, emphasised the significance of making this powerful model accessible for in-house use, ensuring better predictive data and more efficient workflows.


This new assay kit represents a step forward in modernising preclinical testing and improving the success rate of clinical drug candidates. More information online: ilmt.co/PL/A7Xq


63655pr@reply-direct.com


Expanded range of prepacked chromatography columns for biotherapeutic purifi cation


Bio-Rad Laboratories, Inc has introduced the Foresight™ Pro 45 cm inner diameter (ID) chromatography column. Designed to support large-scale downstream purification, the new column provides biopharmaceutical manufacturers with a reliable solution for processing biomolecules such as vaccines, antibodies, and recombinant proteins.


Expanding on the existing Foresight Pro column range, which includes diameters from 5 to 33 cm, the 45 cm ID column offers seamless integration into downstream workflows. Manufactured and packed in an ISO Class 7 cleanroom, these good manufacturing practice (GMP)-ready columns ensure consistency and performance. The standardised design is available in various diameters and bed heights and can be prepacked with CHT™ Ceramic Hydroxyapatite Media Type I, Type II, or XT. CHT Media’s unique composition, Ca10(PO4)6OH2, enables biomolecule purification through metal affinity interactions with calcium atoms and cation exchange interactions via phosphate groups.


“The launch of our 45 cm ID Foresight Pro Column directly responds to customer demand for larger-scale solutions,” said Diab Elmashni, Director of Process Chromatography at Bio-Rad Laboratories. “Unlike other suppliers that may combine multiple resin batches, Bio-Rad’s columns are packed with a single lot of CHT Media, ensuring consistency and superior technical and application support for biopharmaceutical manufacturers.”


More information online: ilmt.co/PL/3ynK 63761pr@reply-direct.com


Direct translocation of proteins into living cells


BioPORTER® protein delivery reagent from AMSBIO is proven to efficiently transport functionally active proteins directly into living cells eliminating the traditional DNA transfection, transcription, and protein translation process.


Employing a unique lipid-based protein delivery system, BioPORTER® makes studying protein functionality faster and easier than ever before. Comprising a proprietary cationic lipid mixture that interacts non-covalently with the protein, BioPORTER® creates a protective vehicle for immediate protein delivery directly into the cell cytoplasm.


BioPORTER® has been demonstrated to be highly effective in delivering a diverse array of proteins, peptides, and other macromolecules into the cytoplasm of many different cells, retaining the structure of the proteins whilst leaving the transduced cells unharmed. The BioPORTER® Reagent is especially useful when studying protein function in cells that are difficult to transfect using traditional DNA transfection reagents, such as human dendritic cells.


Available either as a bulk reagent or convenient single-use QuikEase™ vials, BioPORTER® is extremely easy to use. For maximum speed and convenience, AMSBIO offers the BioPORTER QuikEase™ Kit. Each QuikEase kit contains 96 single reaction size vials that are pre-coated with BioPORTER® reagent. You can either separate each vial for single use or use the entire pack for high-throughput experiments. The BioPORTER QuikEase kit saves hours of time by eliminating the need to coat the BioPORTER® Reagent onto individual vials.


Read AMSBIO’s blog post to learn more about how BioPORTER® has been used in immune cell driven drug delivery for treating neurodegenerative disorders: ilmt.co/PL/65ob More information online: ilmt.co/PL/XNoQ


63449pr@reply-direct.com


MI/MO and NY cannabis residual solvents in two convenient kits


Restek has introduced new certified reference materials (CRM) kits designed for cannabis labs following state-specific residual solvents methods for Michigan, Missouri, and New York. These kits include all compounds listed for these state analyses, ensuring full compliance with local regulatory standards.


The high analyte concentration - up to 5000 μg/mL - makes it easier for labs to quickly and efficiently calibrate their instruments. Restek’s proprietary manufacturing process ensures that these standards are accurate, reproducible, and stable, with a long shelf life that includes even the more challenging gases.


Both kits contain all necessary gas and liquid compounds required by the respective state methods, making them a complete solution for residual solvent testing. Additionally, second independent lots are available, offering labs an added convenience without needing to source materials from another supplier.


The two kits offered include the Michigan & Missouri Residual Solvents Kit and the New York Residual Solvents Kit, each formulated specifically for their respective state requirements. More information online: ilmt.co/PL/OkXN


63497pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44